Published in Clin Cancer Res on March 15, 2007
The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta (2007) 2.82
Urine biomarkers in prostate cancer. Nat Rev Urol (2010) 1.17
Toward the detection of prostate cancer in urine: a critical analysis. J Urol (2012) 1.13
Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol (2008) 1.11
Newer potential biomarkers in prostate cancer. Rev Urol (2007) 1.09
DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn (2009) 1.08
Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer (2011) 1.07
Genomic Rearrangements of PTEN in Prostate Cancer. Front Oncol (2013) 1.07
Quantitative ratiometric discrimination between noncancerous and cancerous prostate cells based on neuropilin-1 overexpression. Proc Natl Acad Sci U S A (2011) 1.02
Urinary biomarkers for prostate cancer: a review. Asian J Androl (2013) 1.02
CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol (2008) 1.00
Promoter hypermethylation in prostate cancer. Cancer Control (2010) 0.99
Aberrant DNA methylation and prostate cancer. Curr Genomics (2011) 0.98
DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy. Br J Cancer (2014) 0.93
APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis. Eur J Hum Genet (2013) 0.92
Promoter Methylation in Prostate Cancer and its Application for the Early Detection of Prostate Cancer Using Serum and Urine Samples. Biomark Cancer (2010) 0.91
Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. Br J Cancer (2014) 0.88
DNA methylation in promoter region as biomarkers in prostate cancer. Methods Mol Biol (2012) 0.88
Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer. World J Gastroenterol (2010) 0.87
The present and future of prostate cancer urine biomarkers. Int J Mol Sci (2013) 0.85
Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer. PLoS One (2014) 0.83
Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis. Curr Med Chem (2012) 0.83
DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer. DNA Cell Biol (2011) 0.82
The association of retinoic acid receptor beta2(RARβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis. PLoS One (2013) 0.81
The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer. Cancers (Basel) (2013) 0.81
Methylated DNA and microRNA in body fluids as biomarkers for cancer detection. Int J Mol Sci (2013) 0.81
Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis. PLoS One (2013) 0.80
Epigenetic regulation of prostate cancer. Clin Epigenetics (2011) 0.79
Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer. Oncotarget (2014) 0.79
Urine markers and prostate cancer. Cent European J Urol (2011) 0.78
Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer. PLoS One (2014) 0.77
DNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer Cells. PLoS One (2016) 0.77
Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach. J Transl Med (2016) 0.75
A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential. J Biomark (2014) 0.75
Tumour biomarkers: homeostasis as a novel prognostic indicator. Open Biol (2016) 0.75
Analysis of DNA Methylation Status in Bodily Fluids for Early Detection of Cancer. Int J Mol Sci (2017) 0.75
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst (2008) 5.82
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ (2012) 4.64
Epidemiology and risk factors of urothelial bladder cancer. Eur Urol (2012) 4.45
Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol (2008) 3.83
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
iTRAQ underestimation in simple and complex mixtures: "the good, the bad and the ugly". J Proteome Res (2009) 3.61
MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol (2011) 3.57
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol (2007) 2.92
The current status of laparoscopic sacrocolpopexy: a review. Eur Urol (2009) 2.85
Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med (2010) 2.83
Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. J Urol (2009) 2.77
Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells. Mol Cell Biol (2002) 2.73
Olfactory detection of prostate cancer by dogs sniffing urine: a step forward in early diagnosis. Eur Urol (2010) 2.72
Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. Control Clin Trials (2003) 2.70
Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst (2004) 2.66
FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol (2008) 2.65
Prospective comparison of radical retropubic prostatectomy and robot-assisted anatomic prostatectomy: the Vattikuti Urology Institute experience. Urology (2002) 2.58
Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res (2009) 2.58
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet (2008) 2.45
Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol (2005) 2.45
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
Laparoscopic and robot assisted radical prostatectomy: establishment of a structured program and preliminary analysis of outcomes. J Urol (2002) 2.43
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet (2011) 2.43
Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. J Clin Epidemiol (2008) 2.40
High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res (2010) 2.39
Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37
Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol (2008) 2.32
Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30
Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol (2013) 2.26
Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol (2005) 2.26
Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol (2011) 2.19
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
Prostate cancer characteristics in a multiracial community. Eur Urol (2007) 2.15
Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol (2006) 2.15
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy. Urology (2012) 2.13
The learning curve of transrectal ultrasound-guided prostate biopsies: implications for training programs. Urology (2013) 2.06
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res (2009) 2.03
Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol (2010) 1.82
Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A (2009) 1.81
Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol (2012) 1.81
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Application of artificial intelligence to the management of urological cancer. J Urol (2007) 1.79
Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression. J Clin Oncol (2013) 1.78
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet (2013) 1.78
A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol (2008) 1.77
Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate (2009) 1.73
Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). J Clin Epidemiol (2003) 1.71
Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. Eur Urol (2013) 1.69
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia (2009) 1.68
Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Res (2012) 1.65
Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial. Eur Urol (2007) 1.64
High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol (2003) 1.63
Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures. Eur Urol (2009) 1.63
The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. Eur Urol (2009) 1.62
Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell (2005) 1.60
Modified supine percutaneous nephrolithotomy for large kidney and ureteral stones: technique and results. Eur Urol (2011) 1.58
Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. Eur Urol (2010) 1.56
Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. Eur Urol (2012) 1.55
Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol (2006) 1.54
The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol (2009) 1.54
Health and quality of life in urology: issues in general urology and urological oncology. Arch Esp Urol (2009) 1.52
Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. J Urol (2010) 1.52